OS Therapies Achieves Full Alignment With UK MHRA On Its Pending Conditional Marketing Authorization Application
MHRA agreed that the use of comparable historical control data – derived from a systematic evaluation of all suitable available peer-reviewed literature by independent biostatistics advisors presented in its most recent
OS Therapies got approval from UK regulators to use old research data. This means the company cleared a big hurdle to sell its medicine there.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.